What's Happening?
The U.S. Food and Drug Administration (FDA) has approved bemotrizinol as a new active ingredient for over-the-counter sunscreens, marking the first such approval in over two decades. Bemotrizinol, which has been used safely in Europe for years, is recognized
for its ability to protect against both UVA and UVB rays. The ingredient is considered Generally Recognized As Safe and Effective (GRASE) by the FDA and is suitable for use by adults and children aged six months and older. This approval is expected to increase competition and consumer confidence in sunscreen products in the U.S., providing stronger broad-spectrum protection against harmful UV rays.
Why It's Important?
The approval of bemotrizinol is significant as it addresses a long-standing gap in the U.S. sunscreen market, where options for broad-spectrum protection have been limited. This development is crucial for public health, as skin cancer remains the most commonly diagnosed cancer in the U.S. Bemotrizinol's photostability and low skin absorption make it a preferable option for consumers, especially those with sensitive skin. The introduction of this ingredient is expected to enhance the effectiveness of sunscreens, potentially reducing the incidence of skin cancer and premature aging caused by UV exposure.
What's Next?
Following the FDA's approval, bemotrizinol will be available in U.S. sunscreens starting August 9, 2026. Initially, it will be marketed under the brand name Parsol Shield by DSM Nutritional Products, with an 18-month exclusivity period. After this period, other manufacturers will be able to incorporate bemotrizinol into their products. This approval is anticipated to lead to a broader range of sunscreen options for U.S. consumers, aligning with international standards and improving overall sun protection.
